PSA‐based screening programs and especially multiparametric MRI (mpMRI) have markedly improved both the detection of clinically significant PCa (csPCa) and the reduction of unnecessary biopsies by enabling better risk stratification and targeted sampling [5-8]. The gene discussed is KLK3; the disease is posterior cortical atrophy.